Figma Inc. Class A Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Figma Inc. Class A Common Stock trades at $21.23 (market cap $11.60B), while Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.2× Figma Inc. Class A Common Stock's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| FIG | ROIV | |
|---|---|---|
Market Cap | $11.60B | $24.99B |
Volume | 12,281,013 | 4,711,562 |
Sector | Technology | Health |
52-Week High | $63.82 | $41.81 |
52-Week Low | $16.84 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $10.00B | $21.25B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.
Read more on FIG →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →